Skip to main content
. 2019 Jul 15;18(3):3049–3057. doi: 10.3892/ol.2019.10613

Figure 3.

Figure 3.

Comparison of plasma levels of LINK-A prior to and after treatment in patients with (A) brain-metastatic NSCLC (B) bone-metastatic NSCLC and (C) liver-metastatic NSCLC. *P<0.05. LINK-A, long intergenic non-coding RNA for kinase activation; NSCLC, non-small cell lung cancer.